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Background: Post-treatment survival experience of early colon cancer (CC) patients is well described in the literature,
which states that cure is probable for some patients. However, comparisons of treated patients’ survival versus that
expected from a matched general population (MGP) are limited.
Patients and methods: A total of 32 745 patients from 25 randomized adjuvant trials conducted from 1977 to 2012 in
41 countries were pooled. Observed long-term survival of these patients was compared with expected survival matched
on sex, age, country, and year, both overall and by stage (II and III), sex, treatment [surgery, 5-ﬂuorouracil (5-FU),
5-FU + oxaliplatin], age (<70 and 70+), enrollment year (pre/post 2000), and recurrence (yes/no). Comparisons were
made at randomization and repeated conditional on survival to 1, 2, 3, and 5 years. CC and MGP equivalence was
tested, and observed Kaplan–Meier survival rates compared with expected MGP rates 3 years out from each landmark.
Analyses were also repeated in patients without recurrence.
Results: Within most cohorts, long-term survival of CC patients remained statistically worse than the MGP, though
conditional survival generally improved over time. Among those surviving 5 years, stage II, oxaliplatin-treated, elderly, and
recurrence-free patients achieved subsequent 3-year survival rates within 5% of the MGP, with recurrence-free patients
achieving equivalence.
Conclusions: Conditional on survival to 5 years, long-term survival of most CC patients on clinical trials remains
modestly poorer than an MGP, but achieves MGP levels in some subgroups. These ﬁndings emphasize the need for
access to quality care and improved treatment and follow-up strategies.
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introduction
Colon cancer (CC) is a leading cause of cancer-related death,
ranking third for both men and women [1] in the USA. In
patients with stage III CC, the beneﬁt of adjuvant chemotherapy
following curative resection has been well established, with the
deﬁnitive trials for FOLFOX [5-ﬂuorouracil (5-FU), leucovorin,
and oxaliplatin] completed roughly one decade ago [2, 3]. The
survival outlook of patients with early-stage CC patients has
also improved over time due to improved diagnostics [4], and in
a pooled analysis of patient-level data, it was demonstrated that
cure is probable in a subset of patients with early-stage CC [5].
However, to date, comparisons of the post-treatment survival
experience of early-stage CC patients versus expected survival
from a matched general population (MGP) have been limited,
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and the timing at which a patient might reasonably be expected
to achieve an equivalent survival outlook to an otherwise similar
non-cancer patient remains a challenging question.
existing population studies in colon cancer
Existing population-based studies in CC are mostly limited to
comparisons between subpopulations of patients with cancer.
For example, Jensen et al. [6] compared survival after colorectal
cancer among Danish patients with and without ulcerative
colitis. A similar population-based comparison of colorectal sur-
vival by patient sex was conducted, but limited to patients in
Germany [7]. On a larger scale, Gatta et al. [8] compared colo-
rectal cancer survival between European and US populations
according to disease subsite and tumor histology, whereas
Allemani et al. [9] attempted to explain persistent survival dif-
ferences between Europe and US populations by accounting for
stage of disease at diagnosis and adherence to treatment guide-
lines. Grouping data on 5489 patients collected from several
population-based data resources, Sanoff et al. [10] investigated
the effect of adjuvant chemotherapy on survival of stage III CC
patients diagnosed at age 75 or later, ﬁnding results consistent
with published trials. Focusing on conditional survival, Chang
et al. [11] created a web-based tool that predicts subsequent sur-
vival of CC patients given survival to speciﬁc thresholds after
initial treatment. A similar study was carried out by Zamboni
et al. [12], where conditional survival and disease-free survival,
were reported for subsets of patients from NSABP trials who
survived without recurrence up to 5 years post-treatment. None
of these recent population-based and trial-based explorations
attempted, however, to compare the post-treatment survival
experience of CC patients against otherwise similar patients
from the general population. As a result, the question of when
the long-term survival of CC patients can be expected to return
to ‘normal’, i.e. to a level consistent with individuals who did
not have CC, remains largely unanswered.
patients andmethods
database
The Adjuvant Colon Cancer Endpoints (ACCENT) database contains
patient-level information on more than 30 000 patients enrolled to 25 phase
III adjuvant CC trials since 1977 [13, 14] (supplementary Table S1, available
at Annals of Oncology online). Using these data, we compared the post-
treatment survival of CC patients against the expected survival of the general
population, where the general population was matched to ACCENT patients
on age, sex, calendar year of evaluation, and country of enrollment.
ACCENT patients with missing data on any matching characteristics were
excluded from these analyses as their expected survival could not be recon-
structed for comparison. Patients receiving adjuvant irinotecan were add-
itionally excluded. Survival, deﬁned as the time from randomization to death
due to any cause, was right-censored at the earlier of loss of follow-up or
8 years. Recurrence times were also recorded and used to subset the ACCENT
data to those patients who were recurrence-free at post-randomization analysis
time points.
construction of matched general population
quantities
For every patient in the ACCENT database, expected long-term survival
based on the general population (matched on age at diagnosis, sex, country
of enrollment, and year of enrollment/evaluation) was derived from life
tables using the methods of Finkelstein et al. [15]. Validated life tables asso-
ciated with speciﬁc countries and years were obtained from the Human
Mortality Database (HMD) or World Health Organization (WHO) for this
analysis [16, 17], where one such table gives the probability that an individ-
ual of a speciﬁc sex and age (in years) will survive 1 year (HMD) or 5 years
(WHO). HMD tables were used for all countries when available, and where
WHO survival tables were used, 1-year incremental probabilities were
derived by assuming a constant risk of death across the 5-year interval.
While age (in years) at randomization was uniformly collected for all
ACCENT trials, exact dates of birth were not uniformly available; as such,
the date and month of birth for each patient was assumed to be equal to the
randomization date for the purpose of referencing life tables.
statistical comparisons
After construction of the ACCENT-matched expected population survival,
long-term comparisons were carried out. First, using randomization date as
the time origin, overall survival (OS) was compared overall between ACCENT
patients and the MGP using a one-sample log-rank test and Kaplan–Meier
analysis tailored for comparisons of a sample against a matched population
constructed from life tables [15]. Speciﬁcally, the standardized mortality ratio
(SMR; ratio of observed-to-expected number of deaths during follow-up) and
associated 95% CI were computed, where intervals excluding SMR = 1 indi-
cated statistically signiﬁcant differences. Separately, a Kaplan–Meier survival
curve with a 95% pointwise conﬁdence band for the ACCENT patients was
superimposed on the (smooth) expected survival curve based on the
ACCENT–MGP. Of particular interest were the observed (ACCENT) minus
expected (matched population) 3-year overall survival rates; these differences
were computed and reported with 95% conﬁdence intervals.
To investigate conditional survival over time of CC patients versus the
general population, the analyses described above were repeated 1, 2, 3, and 5
years post-randomization, with ACCENT patients not surviving to each
landmark excluded and expected survival reconstructed using the new refer-
ence time and relevant ACCENT subset.
All analyses were further carried out both overall and within groups
deﬁned by stage of disease (II and III), sex, age (< 70 and 70+), year of enroll-
ment (pre/post 1 January 2000), grouped treatment (surgery alone, surgery
+ 5-FU, and surgery + FOLFOX), and recurrence before analysis time (yes
and no). As disease recurrence is a time-dependent event of particular inter-
est, results are also presented overall and within the patient subgroups after
subsetting to those patients alive and recurrence-free at post-randomization
analysis times.
results
A total of 32 745 patients from 25 randomized ACCENT trials
conducted in 41 countries had complete data available for ana-
lysis (supplementary Table S2, available at Annals of Oncology
online), whereas 12 patients were excluded for missing data.
Differences in 3-year OS between ACCENT cohorts and MGPs
are presented across conditional survival time points in Table 1,
both overall and by subgroups of interest. The same quantities,
but subsetted to patients who survived without recurrence to
each time point, are presented in Table 2. Corresponding overall
and subgroup-speciﬁc Kaplan–Meier graphs showing up to
8 years of follow-up are presented in Figures 1–3, with base-
line time points of randomization, conditional survival to
5 years, and conditional survival to 5 years without recur-
rence, respectively. SMRs are reported for all time points and
patient subgroups in supplementary Table S3 (overall) and
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supplementary Table S4 (recurrence-free only), available at
Annals of Oncology online. In cases where the 95% CI for the
SMR does not include 1.0, the null hypothesis of equivalent
CC and population survival is rejected at the alpha = 0.05
level (P-values not shown).
From Table 1 and corresponding Figures 1 and 2, we ﬁnd that
3-year survival probabilities for patients with CC do not return
to levels within 5% of a matched population, either overall or
within most patient subgroups, until patients have survived to 5
years post-randomization. Overall, at the time of initial surgery
Table 1. Observed Kaplan–Meier survival rate minus expected (population-matched) survival rate and 95% CI for the difference, expressed as
absolute percentages (%)
Cohort N Randomized
(N = 32 745)
Lived 1 year
(N = 31 122)
Lived 2 years
(N = 28 421)
Lived 3 years
(N = 25 974)
Lived 5 years
(N = 21 949)
Overall 32 745 −14.1 (−14.6, −13.7) −15.8 (−16.3, −15.4) −13.5 (−13.9, −13.0) −10.0 (−10.5, −9.6) −5.2 (−5.7, −4.8)
Stage II 9668 −4.8 (−5.54, −4.2) −6.1 (−6.7, −5.5) −5.9 (−6.5, −5.2) −4.9 (−5.6, −4.2) −2.8 (−3.5, −0.2)
Stage III 23 077 −18.0 (−18.6, −17.5) −20.1 (−20.6, −19.5) −16.9 (−17.5, −16.4) −12.5 (−13.1, −11.9) −6.6 (−7.2, −5.9)
Males 17 867 −13.3 (−13.8, −12.7) −15.5 (−16.1, −14.9) −13.4 (−14.0, −12.8) −10.1 (−10.7, −9.4) −5.2 (−5.9, −4.5)
Females 14 878 −15.2 (−15.8, −14.6) −16.3 (−16.9, −15.6) −13.5 (−14.2, 12.9) −10.0 (−10.6, −9.3) −5.3 (−5.9, −4.6)
Surgery 2326 −18.6 (−20.3, −16.8) −21.1 (−22.9, −19.2) −18.3 (−20.2, −16.3) −13.6 (−15.5, −11.6) −7.1 (−9.1, −4.9)
5-FU 27 150 −14.4 (−14.9, −13.9) −16.1 (−16.6, −15.6) −13.7 (−14.2, −13.2) −10.2 (−10.7, −9.7) −5.2 (−5.7, −4.7)
Oxaliplatin 3269 −8.6 (−9.8, −7.5) −10.2 (−11.5, −9.0) −8.4 (−9.6, −7.2) −6.5 (−7.7, −5.3) −4.5 (−6.3, −2.7)
Age <70 26 700 −14.5 (−15.0, −14.1) −16.6 (−17.1, −16.1) −14.1 (−14.6, −13.6) −10.7 (−11.2, −10.2) −5.7 (−6.2, −5.2)
Age 70+ 6045 −12.4 (−13.5, −11.3) −12.5 (−13.6, −11.4) −10.3 (−11.5, −9.1) −6.7 (−7.9, −5.5) −3.1 (−4.5, −1.6)
Pre-2000a 5667 −15.6 (−16.1, −15.0) −17.5 (−18.1, −17.0) −15.1 (−15.7, −14.5) −11.3 (−11.9, −10.7) −5.3 (−6.0, −4.6)
2000+a 27 078 −10.4 (−11.2, −9.7) −12.6 (−13.3, −11.9) −10.9 (−11.6, −10.2) −8.4 (−9.1, −7.8) −5.1 (−5.8, −4.3)
Recurred (varies) – −77.8 (−79.2, −76.3) −69.0 (−70.3, −67.5) −61.5 (−63.0, −59.9) −46.1 (−48.4, −43.7)
No recur (varies) – −10.1 (−10.5, −9.7) −4.7 (−5.1, −4.3) −1.8 (−2.2, −1.5) −0.2 (−0.6, 0.2)
Estimates are computed 3 years post-randomization and 3 years following conditional survival to years 1, 2, 3, and 5 post-randomization. Patients who
received irinotecan and stage I patients were excluded from all analyses. Entries in bold indicate survival differences from the general population of
<5%. Shaded cells indicate statistical equivalence between colon cancer patients and the matched general population.
aPatients randomized before or after 2000, respectively (grouping fixed over time).
Table 2. Patients without recurrence
Cohort N Randomized
(N = 32 745)
AWR at 1 year
(N = 28 299)
AWR at 2 years
(N = 24 314)
AWR at 3 years
(N = 22 031)
AWR at 5 years
(N = 18 464)
Overall 32 745 −14.1 (−14.6, −13.7) −10.1 (−10.5, −9.7) −4.7 (−5.1, −4.3) −1.8 (−2.2, −1.5) −0.2 (−0.6, 0.2)
Stage II 9668 −4.8 (−5.5, −4.2) −3.7 (−4.2, −3.1) −1.6 (−2.2, −1.1) −0.7 (−1.2, −0.1) 0.2 (−0.4, 0.9)
Stage III 23 077 −18.0 (−18.6, −17.5) −13.1 (−13.6, −12.5) −6.3 (−6.8, −5.8) −2.5 (−2.9, −2.0) −0.5 (−1.0, 0.0)
Males 17 867 −13.3 (−13.8, −12.7) −10.2 (−10.7, −9.6) −4.8 (−5.3, −4.2) −1.7 (−2.3, −1.2) −0.2 (−0.8, 0.4)
Females 14 878 −15.2 (−15.8, −14.6) −10.0 (−10.6, −9.4) −4.7 (−5.2, −4.1) −1.9 (−2.4, −1.5) −0.2 (−0.7, 0.3)
Surgery 2326 −18.6 (−20.3, −16.8) −12.4 (−14.1, −10.6) −7.1 (−8.9, −5.4) −4.1 (−5.8, −2.4) −1.6 (−3.5, 0.3)
5-FU 27 150 −14.4 (−14.9, −13.9) −10.5 (−10.9, −10.0) −4.9 (−5.3, −4.5) −2.0 (−2.4, −1.6) −0.1 (−0.6, 0.3)
Oxaliplatin 3269 −8.6 (−9.8, −7.5) −5.7 (−6.8, −4.6) −1.9 (−2.8, −0.9) 0.4 (−0.4, 1.3) −0.1 (−1.7, 1.5)
Age <70 26 700 −14.5 (−15.0, −14.1) −10.7 (−11.1, −10.2) −5.2 (−5.6, −4.8) −2.4 (−2.8, −2.0) −0.5 (−0.9, 0.0)
Age 70+ 6045 −12.4 (−13.5, −11.3) −7.4 (−8.5, −6.4) −2.4 (−3.5, −1.3) 0.8 (−0.2, 1.9) 1.0 (−0.4, 2.4)
Pre-2000a 5667 −15.6 (−16.1, −15.0) −11.9 (−12.5, −11.4) −6.4 (−6.9, −5.9) −3.2 (−3.7, −2.7) −0.3 (−0.9, 0.3)
2000+a 27 078 −10.4 (−11.2, −9.7) −6.6 (−7.2, −6.0) −2.1 (−2.6, −1.6) −0.1 (−0.6, 0.4) 0.1 (−0.6, 0.7)
Observed Kaplan–Meier survival rate minus expected (population-matched) survival rate and 95% CI for the difference, expressed as absolute
percentages (%). Estimates are computed 3 years post-randomization and 3 years following conditional survival to years 1, 2, 3, and 5 post-
randomization without recurrence. Patients who received irinotecan and stage I patients were excluded from all analyses. Entries in bold indicate
survival differences from the general population of <5%. Shaded cells indicate statistical equivalence between colon cancer patients and the matched
general population.
aPatients randomized before or after 2000, respectively (fixed over time).
AWR, alive without recurrence.
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Figure 1. Kaplan–Meier survival curves for ACCENT patients from randomization with 95% pointwise CI, superimposed on matched population survival
curves, (A) overall and by (B) sex, (C) stage of disease, (D) treatment, (E) age group, and (F) enrollment year.
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or adjuvant treatment, the 3-year survival rate of all patients
with early-stage (II and III) CC is 14.1% less than the MGP,
with subsequent 3-year survival improving to only 5.2% less
than the general population given survival to 5 years. Patients
who survive without recurrence to 2 years, however, show subse-
quent 3-year survival only 4.7% less than the MGP. Those who
additionally survive without recurrence to 5 years eventually
achieve subsequent 3-year survival rates that are statistically
comparable to the general population, as indicated by the
expected general population rate falling within the 95% interval
for the CC patient rate and an SMR statistically indistinguish-
able from 1.0. Another cohort with improved outcomes are
patients with stage II disease, whose 3-year survival rate is only
4.8% less than the general population immediately following
treatment, and only 2.8% less than the general population given
survival to 5 years. As expected, the difference in 3-year survival
between ACCENT patients and the MGP varies according to
treatment received, with oxaliplatin-treated patients showing
the best long-term outcomes, achieving subsequent 3-year sur-
vival only 4.5% less than the general population given survival
to 5 years. At the same time point, patients treated with adjuvant
5-FU and those receiving surgery only have 3-year survival rates
of 5.2% and 7.1% less than the general population, respectively.
The difference in 3-year survival rate between patients with CC
and the MGP is worse at the time of initial treatment of females
than for males, but this difference becomes negligible condition-
al on survival to later years. The difference in 3-year survival
rate between patients with CC and the general population is
slightly worse for individuals <70 versus >70 years of age, and
remains consistently so over subsequent conditional survival
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Figure 2. Kaplan–Meier survival curves for ACCENT patients with 95% pointwise CI, superimposed on matched population survival curves, (A) overall and
by (B) sex, (C) stage of disease, (D) treatment, (E) age group, (F) enrollment year, and (G) recurrence, conditional on survival to 5 years.
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time points. Patients initiating treatment after 2000 show smaller
differences in 3-year survival rate relative to the general popula-
tion across all time points, compared with patients who were
treated before 2000. Those patients who survive to 2, 3, and 5
years post-randomization but are known to have had a recurrence
demonstrate large differences in 3-year survival rate relative to the
general population, ranging from a 77.8% decrease in subsequent
3-year survival at 1 year to a 46.1% decrease in subsequent 3-year
survival at 5 years.
Overall, incidence or absence of disease recurrence is the stron-
gest factor predicting the ACCENT patients’ subsequent survival
experience as well as differences from the general population.
Patients who remain alive and recurrence-free show a high likeli-
hood of achieving an expected long-term survival similar to that
of the general population as they reach additional year landmarks,
with statistical equivalence of subsequent 3-year survival achieved
at 5 years post-treatment without recurrence (overall and for all
subgroups). This equivalence is reached even sooner (by 3 years)
for patients who are treated with adjuvant oxaliplatin, patients
who are 70 years of age or older, and those who were treated after
the year 2000.
discussion
CC remains a leading cause of cancer-related death, despite
therapeutic advances. However, the survival experience of early-
stage CC patients has improved in recent years, with cure possible
for many patients. In this study, we addressed the questions of
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Fig. 2 Continued
Volume 26 | No. 5 | May 2015 doi:10.1093/annonc/mdv073 | 
Annals of Oncology original articles
General population
Colon cancer without recurrence
5.0
0.0
0.2
0.4
Su
rv
iva
l p
ro
ba
bi
lity
0.6
0.8
1.0
Colon cancer survival versus general population
patients without recurrence
A B
C D
5.5 6.5
Years since treatment initiation
7.56.0 7.0 8.0
Female matched general population
Male matched general population
Colon cancer in females without recurrence (95% CI)
Colon cancer in males without recurrence (95% CI)
5.0
0.0
0.2
0.4
Su
rv
iva
l p
ro
ba
bi
lity
0.6
0.8
1.0
Colon cancer survival by sex versus general population
patients without recurrence
5.5 6.5
Years since treatment initiation
7.56.0 7.0 8.0
Stage III matched general population
Stage II matched general population
Stage II colon cancer without recurrence (95% CI)
Stage III colon cancer without recurrence (95% CI)
5.0
0.0
0.2
0.4
Su
rv
iva
l p
ro
ba
bi
lity
0.6
0.8
1.0
Colon cancer survival by stage versus general population
patients without recurrence
5.5 6.5
Years since treatment initiation
7.56.0 7.0 8.0
Surgery matched general population
5FU matched general population
Surgery alone without recurrence (95% CI)
5FU without recurrence (95% CI)
Oxaliplatin without recurrence (95% CI)
Oxaliplatin matched general population
5.0
0.0
0.2
0.4
Su
rv
iva
l p
ro
ba
bi
lity
0.6
0.8
1.0
Colon cancer survival by treatment versus general population
patients without recurrence
5.5 6.5
Years since treatment initiation
7.56.0 7.0 8.0
Age 70+ matched general population
Age < 70 matched general population
Colon cancer in age < 70 without recurrence (95% CI)
Colon cancer in age 70+ without recurrence (95% CI)
Age 2000+ matched general population
Year < 2000 matched general population
Colon cancer treated pre-2000 without recurrence (95% CI)
Colon cancer treated in 2000 or later without recurrence (95% CI)
5.0
0.0
0.2
0.4
Su
rv
iva
l p
ro
ba
bi
lity
0.6
0.8
1.0
Colon cancer survival by age group versus general population
patients without recurrence
E F
5.5 6.5
Years since treatment initiation
7.56.0 7.0 8.0 5.0
0.0
0.2
0.4
Su
rv
iva
l p
ro
ba
bi
lity
0.6
0.8
1.0
Colon cancer survival by era versus general population
patients without recurrence
5.5 6.5
Years since treatment initiation
7.56.0 7.0 8.0
Figure 3. Kaplan–Meier survival curves for ACCENT patients without recurrence with 95% pointwise CI, superimposed on matched population survival
curves, (A) overall and by (B) sex, (C) stage of disease, (D) treatment, (E) age group, and (F) enrollment year, conditional on survival to 5 years.
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when and under what conditions the post-treatment survival of
early-stage CC patients can reasonably be expected to resemble
that of a cohort of similar individuals from the same country, age,
and year in time. These results may also shed light on the
expected prognoses of individual patients as they survive to
annual landmarks.
As expected, we found that disease recurrence plays the stron-
gest role in determining subsequent survival experiences relative
to the general population, while stage of disease and treatment
also factor strongly. While differences in conditional survival
between ACCENT and matched cohorts generally lessen over
time beyond the 1-year landmark, there is a subtle increase in
the difference between CC and population survival that occurs
from randomization to year 1 (Table 1), perhaps reﬂecting that
the ﬁrst 1–2 years post-treatment is the time of highest risk of
recurrence. Also of note is the strong separation of risk differ-
ences evident for patients younger than 70 versus those 70 or
older, with patients younger than 70 experiencing greater differ-
ences in survival compared with the general population, relative
to elderly patients. Two factors are likely at play here on oppos-
ite ends of the age spectrum: delayed diagnosis in young CC
patients having a detrimental impact on survival [18], and an
increased likelihood for all causes of death among elderly
patients from both the ACCENT and general populations. In
fact, elderly patients who survive without recurrence to 5 years
post-treatment exhibit statistically greater subsequent survival
relative to their MGP (supplementary Table S4, available at
Annals of Oncology online), reﬂecting the likelihood that elderly
patients who are eligible for trials may be otherwise healthier or
ﬁtter than their counterparts from the general population.
One recognized limitation of this study is restriction of
consideration to CC patients who were sufﬁciently healthy to be
eligible for inclusion in clinical trials. Trial patients generally
have less comorbidity than non-trial patients with the same
disease, affecting generalizability of our prognostic conclusions
to the broader disease population. However, these ﬁndings
could remain clinically useful as a reference point when discuss-
ing prognosis with CC patients who have few comorbidities.
Another limitation of our analysis is its inherent restriction
to those trials for which patient-level data were provided to the
ACCENT group (Supplementary Table S1, available at Annals
of Oncology online). While ACCENT remains the single largest
database of clinical trials for adjuvant therapy in CC created to
date and contains patient data from most of the trials that have
changed clinical practice, not every major randomized study in
adjuvant CC is presently contained in ACCENT. At the same
time, we note that our study offers strengths that would be difﬁ-
cult to achieve using individual population-based patient reposi-
tories as an alternative. Speciﬁcally, through use of the broadly
multinational ACCENT database containing prospectively col-
lected patient data from 41 countries, our work generalizes
to cancer patients internationally as well as locally. The detailed
and rigorous collection of covariates and outcomes within the
included trials also strengthens conﬁdence in our ﬁndings.
In conclusion, a large international comparison of the long-
term survival of >30 000 CC patients contained in the ACCENT
database with their expected survival from an MGP has revealed
subgroups of patients who ultimately achieve post-treatment
survival similar to individuals without cancer. These similarities
occur relatively late, and are strongly dependent on the patient’s
disease not recurring, emphasizing the need for improved access
to quality cancer care and continuing advances in treatment.
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Background: We undertook the present analysis to examine the shifting inﬂuence of prognostic factors in HIV-positive
patients diagnosed with aggressive non-Hodgkin lymphoma (NHL) over the last two decades.
Patients and methods: We carried out a pooled analysis from an existing database of patients with AIDS-related
lymphoma. Individual patient data had been obtained prior from prospective phase II or III clinical trials carried out
between 1990 until 2010 in North America and Europe that studied chemo(immuno)therapy in HIV-positive patients diag-
nosed with AIDS-related lymphomas. Studies had been identiﬁed by a systematic review. We analyzed patient-level data
for 1546 patients with AIDS-related lymphomas using logistic regression and Cox proportional hazard models to identify
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